Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

One of the biggest challenges in cancer treatment is chemoresistance: Tumors that initially respond well to chemotherapy ...

Niraparib significantly improved PFS and time without symptoms for women with advanced ovarian cancer who responded to ...

Myriad Genetics (($MYGN)) announced an update on their ongoing clinical study. Myriad Genetics (MYGN) is collaborating on a clinical study titled ...

Gerhardt Attard, M.D., Ph.D., from University College London, and colleagues conducted a double-blind trial that evaluated combining niraparib with AAP versus placebo and AAP in mCSPC with HRR gene ...

A major international study led by UCL researchers has found that combining two cancer drugs could substantially slow the progression of a severe and often deadly form of prostate cancer in men with ...

Among patients with prostate cancer with homologous recombination repair mutations (HRRm) receiving Akeega (niraparib and ...

A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay ...

A targeted drug combination delays advanced prostate cancer in men with specific DNA repair gene mutations. A large international study led by researchers at UCL has found that a new combination of dr ...

Naked mole-rats seem to have found nature’s cheat code for longevity. Scientists discovered that small tweaks in one of their ...

In the randomized, double-blind, phase III TALAPRO-2 trial, men received either talazoparib plus enzalutamide or placebo plus enzalutamide as initial treatment for mCRPC. 1,2 Patients were recruited ...

“You can see that there was an initial reduction in the HR-QOL score in the niraparib arm, which may have been explained by the onset of the most frequently observed adverse events, which included ...